Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.

David J. Straus,Graham P. Collins,Jan Walewski,Pier Luigi Zinzani,Andrew Grigg,Anna Sureda,Árpád Illés,Tae Min Kim,Sergey Alekseev,Lena Specht,Valeria Buccheri,Anas Younes,Joseph M. Connors,Andres Forero-Torres,Keenan Fenton,Ashish Gautam,Indra Purevjal,Rachael Liu,Andrea Gallamini

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.

2020

David J. Straus
Graham P. Collins
Jan Walewski
Pier Luigi Zinzani
Andrew Grigg
Anna Sureda
Árpád Illés
Tae Min Kim
Sergey Alekseev
Lena Specht
Valeria Buccheri
Anas Younes
Joseph M. Connors
Andres Forero-Torres
Keenan Fenton
Ashish Gautam
Indra Purevjal
Rachael Liu
Andrea Gallamini

We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin...

Keywords:

in patient
Doxorubicin
Medicine
Brentuximab vedotin
Oncology
newly diagnosed
hodgkin lymphoma
Internal medicine
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations